Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (256)	10/13/1998 11:43:00 AM
From: rkrw	Read Replies (1) \| Respond to of 3044

Rick, Can you explain what you mean by...." That would mean that a cox-2 inhibitor is back on the market."? The Cox-2 inhib should be MTC's flagship drug in the near future and is projected to be a multi-billion dollar drug. PFE paid them a boatload of cash upfront for rights to co-market. Naturally the PFE/MTC deal was inked before AHP came into the picture. A Bayer/MTC combo may have too many regulatory hurdles to clear. No way a DD/MTC merger would fly. Both MTC and Bayer have simply whopping committments to MLNM, I just dont see much disrupting this.